Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.
Phillipe MoreauRazi GhoriMohammed FarooquiPatricia MarinelloJesús San F MiguelPublished in: British journal of haematology (2021)